In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Time Dilation

Executive Summary

The faster we appear to be moving in discovery, it seems, the more pronounced the gap between technology advances and product commercialization. When we get back to earth-bound reality, new products aren't getting to the market any faster than they used to, and the speed of physician adoption appears to be a constant. The idea plays out in drug development, where we have to take the time to study the effect of a drug candidate in man before we can determine what clinical questions researchers should ask, much less what the answers are. It will also play out in personalized medicine: We're still not to the point where the first SNP panel has made its way into a pivotal trial, much less to regulatory agencies, physicians, or patient/consumers. That means the debate about the social or ethical ramifications of collecting and using pharmacogenomic information, and an understanding of the basis for the forces that will push against rapid adoption are premature. In a manner of speaking, we haven't even gotten to the stage of testing our responses in patieants.

You may also be interested in...



Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

China VBP, Localization And Other Strategies - How Far And Which Way?

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.

Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use

The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001673

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel